 Home > Biochemistry News > Biotechnology News > Ovid/AstraZeneca Collaboration to Develop Epilepsy Therapy for Novel Target

Ovid/AstraZeneca Collaboration to Develop Epilepsy Therapy for Novel Target

 Last Update: 2022-02-24
 Source: Internet
 Author: User

Tags

3 5 dimethylphenol

blood work novel

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On January 3, 2022, Ovid Therapeutics announced that it had entered into an exclusive license agreement with AstraZeneca to acquire AstraZeneca's early development stage small molecule library targeting the KCC2 transporter, including lead candidate OV350

KCC2 is a potassium chloride cotransporter responsible for maintaining chloride homeostasis in neurons

Under the terms of the agreement, AstraZeneca will receive an upfront payment of $5 million and Ovid stock worth $7.

References:

[1] Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators.

(WuXi AppTec)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.